Crucell signs vaccine production deal with Merck

|

crucell AMSTERDAM, Dec 27 (Reuters) - Dutch biotechnology firm Crucell (CRCL.AS, CRXL.O) said on Wednesday it has signed a cross-licensing agreement with U.S. drugmaker Merck (MRK.N) on its vaccine production technology.

"This agreement will make it possible to speed up the delivery of our malaria and TB vaccines to the people in need, and makes it realistic to do so on the mass scale required," Jaap Goudsmit, chief scientific officer at Crucell, said in a statement.

© Reuters 2006